Blueshift Asset Management’s Orphazyme A/S ORPH Stock Holding History

Blueshift Asset Management’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-82,336	Closed	-$338K	–	1338
2021 Q3	$338K	Buy	82,336 +11,159	+16%	+$57.4K	0.02%	767
2021 Q2	$523K	Buy	+71,177	New	+$574K	0.03%	551

Other funds holding ORPH

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.64B AUM 83.38% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Blueshift Asset Management's ORPH Position: Q4 2021 in Review

Blueshift Asset Management sold out of Orphazyme A/S (ORPH) in Q4 2021, closing a stake of 82,336 shares — an estimated $338K sold.

Blueshift Asset Management first reported a position in ORPH in Q2 2021 and held it in 2 quarters. The position peaked at $523K in Q2 2021. 20 funds tracked by Wall St. Rank hold ORPH as of Q4 2021.

Blueshift Asset Management reported no remaining Orphazyme A/S position as of Q4 2021 after selling out during the quarter.
Blueshift Asset Management sold 82,336 Orphazyme A/S shares in Q4 2021, an estimated $338K.
Blueshift Asset Management first reported a position in Orphazyme A/S in Q2 2021 and held it in 2 quarters.
Blueshift Asset Management's Orphazyme A/S position peaked at $523K in Q2 2021.
20 funds tracked by Wall St. Rank held Orphazyme A/S as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.